Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences (NASDAQ: IDYA) reported a strong financial position with approximately $368 million in cash as of December 31, 2021, sufficient to fund operations into 2025. The company is actively enrolling patients in Cohort 6 of the IDE397 clinical trial, revealing no serious drug-related adverse events. IDEAYA aims to expand its monotherapy and combination cohorts for IDE397 by mid-2022. Additionally, promising results from the darovasertib and crizotinib combination therapy have shown a 100% disease control rate in uveal melanoma patients, showcasing robust clinical activity and manageable side effects.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced promising interim Phase 1 clinical data for IDE397, a MAT2A inhibitor targeting solid tumors with MTAP gene deletions. The trial showed preclinical tumor SDMA suppression of 95-100% and robust plasma SAM modulation exceeding a 60% reduction. Cohort 5 reports a 95% reduction in tumor SDMA without drug-related serious adverse events. IDEAYA is expanding into monotherapy cohorts and targeting a data package delivery to GSK by mid-2022, potentially earning a $50 million option payment and up to $465 million in milestones.

IDEAYA Biosciences (IDYA) has collaborated with Pfizer (PFE) to enhance clinical trials evaluating the combination of darovasertib and crizotinib in patients with metastatic uveal melanoma (MUM) and cMET-driven tumors. The Phase 2 trial could enable registration, with promising preliminary data showing robust activity. IDEAYA plans to provide an update on clinical data in mid-2022 and will seek FDA guidance for trial design. This partnership aims to elevate treatment standards for patients with high unmet needs and potentially expand to other cancer types.

IDEAYA Biosciences (NASDAQ: IDYA) is set to host an Investor Webcast on March 15, 2022, to discuss interim clinical data for IDE397, a potential MAT2A inhibitor in a Phase 1 clinical trial. This trial focuses on patients with tumors featuring MTAP deletions. The call will cover dose escalation data, adverse events, and pharmacokinetic information, alongside the financial results for Q4 and the full year 2021. The company emphasizes its commitment to precision oncology through targeted therapeutic development.

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, announced its participation in several investor conferences in March 2022. Key events include the Guggenheim 3rd Annual Healthy Altitudes CEO Summit on March 10, the Oppenheimer Targeted Oncology Panel on March 14, and the 34th Annual Roth Conference on the same day. CEO Yujiro Hata and CFO Paul Stone will represent the company. Live audio webcasts will be available on IDEAYA's website, with replays accessible for 30 days following the events.

IDEAYA Biosciences (NASDAQ: IDYA) announced participation in Guggenheim Oncology Day on February 9, 2022, at 3:30 PM ET. CEO Yujiro Hata will engage in a fireside chat hosted by Charles Zhu, Ph.D. A live audio webcast will be accessible through IDEAYA’s website, with a replay available for 30 days post-event. IDEAYA focuses on precision medicine for oncology, utilizing synthetic lethality to develop targeted therapeutics based on molecular diagnostics. For more details, visit the Investor Calendar.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced the initiation of IND-enabling studies for IDE161, a potential first-in-class PARG inhibitor. The company has exercised its option for an exclusive worldwide license from Cancer Research UK and the University of Manchester. IDE161 targets tumors with homologous recombination deficiencies, including those with BRCA1 and BRCA2 mutations. IDEAYA plans to submit an IND application for IDE161 in Q4 2022, following successful preclinical studies. The company holds comprehensive rights to IDE161 under its licensing agreement.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced key corporate updates ahead of the J.P. Morgan 40th Annual Healthcare Conference on January 11, 2022. The company reported a robust balance sheet with approximately $386 million in cash and equivalents, expected to fund operations into 2025. They completed enrollment in the Phase 1 trial for IDE397, targeting FDA amendment in Q1 2022. Additionally, IDEAYA aims to submit IND for a PARG inhibitor by Q4 2022 and expand indications for darovasertib. GSK milestone payments of $70 million could be triggered through upcoming developments.

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced on January 5, 2022, the acquisition of its INQUIRE™ Chemical Library, a curated collection of over 200,000 compounds aimed at enhancing the company's synthetic lethality drug discovery platform. This acquisition is expected to improve IDEAYA's hit discovery capabilities across challenging targets such as helicases and endonucleases. The company aims to leverage this proprietary library alongside its existing expertise in drug discovery, aiming for advancements in targeted therapeutics and innovative drug candidates.